ALK and non-small cell lung carcinoma: To overcome these limitations, we developed a novel enzyme-linked immunosorbent assay (ELISA) to rapidly and quantitatively detect and measure ALK-specific antibodies in the serum of patients with ALK-positive NSCLC.